Although there have been multiple observations that SGLT2 inhibitors showed anti-inflammatory results, such as atherosclerosis, myocardial infarction, and renal injury [25,26,27,28], SGLT2 inhibition has not been proposed as a cause of the anti-inflammatory effects of another SGLT2 inhibitor, dapagliflozin [23]. The gene discussed is SLC5A2; the disease is atherosclerosis.